Cognition Therapeutics (NASDAQ:CGTX) President & CEO Lisa Ricciardi joins Natalie Stoberman from the Proactive newsroom to discuss the company's unique focus on the treatment of Lewy body Dementia as well as other cognitive diseases like Alzheimer's Disease.
Cognition is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The company is currently investigating its lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).